Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kaleido Biosciences Inc (KLDO)

Kaleido Biosciences Inc (KLDO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 242,269
  • Shares Outstanding, K 42,578
  • Annual Sales, $ 975 K
  • Annual Income, $ -81,620 K
  • 60-Month Beta -0.31
  • Price/Sales 249.79
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KLDO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.35
  • Most Recent Earnings N/A on 08/11/21
  • Next Earnings Date 11/01/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    Medical - Biomedical

    Indices Russell 2000

Options Overview Details

View History
  • Implied Volatility 144.14%
  • Historical Volatility 55.74%
  • IV Percentile 84%
  • IV Rank 52.73%
  • IV High 194.06% on 03/01/21
  • IV Low 88.45% on 06/09/21
  • Put/Call Vol Ratio 0.04
  • Today's Volume 24
  • Volume Avg (30-Day) 231
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 381
  • Open Int (30-Day) 354

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.55
  • Number of Estimates 3
  • High Estimate -0.44
  • Low Estimate -0.65
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.26 +7.71%
on 09/16/21
6.74 -16.02%
on 09/03/21
-0.40 (-6.60%)
since 08/23/21
3-Month
5.10 +10.89%
on 07/27/21
9.47 -40.23%
on 06/24/21
-1.33 (-19.03%)
since 06/23/21
52-Week
5.10 +10.89%
on 07/27/21
20.50 -72.39%
on 01/28/21
+0.57 (+11.20%)
since 09/23/20

Most Recent Stories

More News
Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates

Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

KLDO : 5.66 (-0.53%)
Kaleido Biosciences Reports Second Quarter 2021 Financial Results

--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter--

KLDO : 5.66 (-0.53%)
Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today...

KLDO : 5.66 (-0.53%)
Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today...

KLDO : 5.66 (-0.53%)
Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth Conference

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today...

KLDO : 5.66 (-0.53%)
Avoid These 3 Downgraded Stocks in June

If you're looking for a second opinion on your stocks, look no further than our proprietary POWR Ratings. Our ratings evaluate stock based on 118 different factors. Stocks that were downgraded to a Sell...

SPWR : 22.53 (+1.26%)
KLDO : 5.66 (-0.53%)
OCGN : 7.61 (+1.47%)
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health...

FHTX : 15.02 (+4.74%)
SANA : 23.01 (+2.82%)
SGTX : 5.80 (+7.01%)
AXLA : 3.07 (unch)
CDAK : 18.85 (+4.43%)
EVLO : 7.47 (+1.08%)
KLDO : 5.66 (-0.53%)
MRNA : 454.60 (+3.15%)
RUBY : 19.30 (-0.05%)
MCRB : 7.09 (+1.00%)
Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today...

KLDO : 5.66 (-0.53%)
Avoid These 3 Stocks

The stock market's attempt to make new highs was rejected this morning. Sometimes, this can lead to additional selling pressure. Certain stocks are more vulnerable in this environment. Find out why Kaleido...

KLDO : 5.66 (-0.53%)
VERB : 1.8600 (+1.64%)
VISL : 1.9300 (+6.04%)
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 3.07 (unch)
CDAK : 18.85 (+4.43%)
DNLI : 52.90 (+1.77%)
EVLO : 7.47 (+1.08%)
FHTX : 15.02 (+4.74%)
KLDO : 5.66 (-0.53%)
MCRB : 7.09 (+1.00%)
MRNA : 454.60 (+3.15%)
RUBY : 19.30 (-0.05%)
SANA : 23.01 (+2.82%)
SGTX : 5.80 (+7.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kaleido Biosciences Inc. is a clinical-stage healthcare company. It focuses on leveraging the potential of the microbiome organ to treat disease and improve human health. The Company's product candidates are Microbiome Metabolic Therapies(TM), which are designed to modulate the metabolic output and profile...

See More

Key Turning Points

3rd Resistance Point 6.12
2nd Resistance Point 5.98
1st Resistance Point 5.82
Last Price 5.66
1st Support Level 5.52
2nd Support Level 5.38
3rd Support Level 5.22

See More

52-Week High 20.50
Fibonacci 61.8% 14.62
Fibonacci 50% 12.80
Fibonacci 38.2% 10.99
Last Price 5.66
52-Week Low 5.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar